China’s open-source LLMs are looking for new ways to make money overseas
AI companies are tightening open-source licenses as soaring agent workloads turn token consumption into a potential…
Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
Backed by an $8.4 billion international licensing deal with Bristol Myers Squibb, Biokin’s groundbreaking dual-target therapy…
Chinese innovative drug makers step onto the global stage through licensing and foreign co-co deals
By Da Cheung In 2025, China’s innovative pharmaceutical companies quietly crossed a historic threshold, overtaking the…
Latest
- After forced Meta split, AI startup Manus regroups with new $500 million funding
- China’s maturing energy storage sector creates giants, leaves behind trail of bankruptcies
- A Guangzhou factory bet big on robots. Its customers only wanted them to carry more.
- China’s satellite IoT bet: small data, big business
- Tactile sensor maker Tashan targets IPO after completing share reform
